scholarly journals Comparison of albumin dialysis devices molecular adsorbent recirculating system and ADVanced Organ Support system in critically ill patients with liver failure—A retrospective analysis

Author(s):  
Christoph Falkensteiner ◽  
Andreas Kortgen ◽  
Julia Leonhardt ◽  
Michael Bauer ◽  
Christoph Sponholz
2001 ◽  
Vol 12 (suppl 1) ◽  
pp. S75-S82
Author(s):  
STEFFEN R. MITZNER ◽  
JAN STANGE ◽  
SEBASTIAN KLAMMT ◽  
PIOTR PESZYNSKI ◽  
REINHARDT SCHMIDT ◽  
...  

Abstract.Liver failure resulting from different causes and its concomitant complications represent difficult-to-treat conditions with high mortality rates, despite improved therapeutic modalities in intensive care medicine. The accumulation of albumin-bound metabolites that are normally cleared by the liver, such as bilirubin and bile acids, contributes substantially to the development of multiorgan dysfunction in these clinical situations. The molecular adsorbent recirculating system (MARS) represents a cell-free, extracorporeal, liver assistance method for the selective removal of albumin-bound substances. Moreover, it enables the removal of excess water and water-soluble substances via an inbuilt dialysis step. Since 1993, >400 patients have been treated in 53 centers in Europe, the United States, and Asia. Diseases treated with MARS included acute exacerbation of chronic hepatic failure, hepatorenal syndrome, acute hepatic failure, and primary nonfunction/poor function after liver transplantation and major liver resection. Treatments were well tolerated. No severe adverse events were observed. Six- to 8-h MARS treatments resulted in significant (P< 0.05) removal of bilirubin, bile acids, tryptophan, shortand middle-chain fatty acids, aromatic amino acids, and ammonia. Clearance rates for strongly albumin-bound substances were between 10 and 60 ml/min. The removal of albumin-bound toxins resulted in decreases in hepatic encephalopathy, increases in mean arterial pressure, and improvements in kidney and liver function. In the first randomized clinical trial of the MARS method for treatment of the hepatorenal syndrome, significant prolongation of survival was observed for the MARS-treated group. It is concluded that the MARS method can contribute to the treatment of critically ill patients with liver failure and different underlying diseases.


2011 ◽  
Vol 10 ◽  
pp. S70-S76 ◽  
Author(s):  
Ramón A. Kobashi-Margáin ◽  
Juan G. Gavilanes-Espinar ◽  
Ylse Gutiérrez-Grabe ◽  
Ángel A. Gutiérrez-Jiménez ◽  
Norberto Chávez-Tapia ◽  
...  

Hepatology ◽  
2013 ◽  
Vol 57 (3) ◽  
pp. 1153-1162 ◽  
Author(s):  
Rafael Bañares ◽  
Frederik Nevens ◽  
Fin Stolze Larsen ◽  
Rajiv Jalan ◽  
Agustín Albillos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document